# Keeping RAASi Treatment With Optimal Potassium Control

> **NCT06578533** · PHASE3 · RECRUITING · sponsor: **Fundación para la Investigación del Hospital Clínico de Valencia** · enrollment: 78 (estimated)

## Conditions studied

- Chronic Kidney Diseases

## Interventions

- **DRUG:** Sodium Zirconium Cyclosilicate

## Key facts

- **NCT ID:** NCT06578533
- **Lead sponsor:** Fundación para la Investigación del Hospital Clínico de Valencia
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-09-30
- **Primary completion:** 2025-07-30
- **Final completion:** 2026-07-30
- **Target enrollment:** 78 (ESTIMATED)
- **Last updated:** 2024-08-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06578533

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06578533, "Keeping RAASi Treatment With Optimal Potassium Control". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT06578533. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*